<International Circulation> : The elderly population in China is growing very quickly and the efficacy and safety of blood pressure lowering in elderly patients with diabetes has not been sufficiently investigated. What are your views of treatment in elderly patients with diabetes?

   《国际循环》：因为高血压患者在老年人群的比例迅速上升，特别是在中国。老年患者降压治疗的安全性和有效性还未得到充分调查时，却又诊断出糖尿病。我们想知道，对于这类人群的治疗是否和其它糖尿病患者不同？您对治疗方案会做何改变或调整？

    Professor Chalmers : I  think the elderly should be treated at least as assiduously as the rest of the patients. In the general population， we have studies not only in the ordinary elderly (70~80 yrs) in SHEP， etc. but we also have HYVET which goes above age 80. In diabetes we do not have specific trials but significant portions of the other studies have included diabetic patients and there is no evidence of heterogeneity between the diabetic and non-diabetic populations in the elderly. My feeling is that until here is definitive evidence available it would be wise to extrapolate from the general population to the diabetic population and continue to treat the elderly.

    Chalmers教授：我认为老年患者的降压治疗措施应该和其它患者一致。我们目前已经研究的老年患者通常指70-80岁这一人群。对于糖尿病患者降压治疗我们未进行特殊试验，但这些降压研究中最重要的患者包括糖尿病患者。而且在糖尿病患者和非糖尿病老年患者研究未发现两者治疗结果存在差异。我觉得目前有明确证据表明降压治疗应该从普通人群发展到糖尿病患者至老年患者。

上一页  [1]  [2]  [3]  [4]  下一页